The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Breviscapin     (2S,3S,4S,5R,6S)-6-[5,6- dihydroxy-2-(4...

Synonyms: Scutellarin, Breviscapine, Scutellarin B, CHEMBL487805, AG-E-88579, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Scutellarin


Psychiatry related information on Scutellarin


High impact information on Scutellarin

  • Pharmacokinetics and metabolism of the flavonoid scutellarin in humans after a single oral administration [6].
  • The Tmax was late (7.85 +/- 1.62 h), and part of individual pharmacokinetic profiles showed double peaks, which indicated scutellarin could be absorbed into the intestine after hydrolysis to its aglycone by bacterial enzymes [6].
  • Moreover, the combination of compounds from different classes offers enhanced potential therapeutic benefits; the combination of SM-470 with scutellarin, Cam-300 or baicalin, augmented the inhibition of cell proliferation [4].
  • By comparing the inhibitory effects on p24 antigen, scutellarin was also found to be active against HIV-1(74V) (EC(50) 253muM) and HIV-1(KM018) (EC(50) 136muM) infection with significant difference in potency [2].
  • From syncytia inhibition study, the EC(50) of scutellarin against HIV-1(IIIB) direct infection in C8166 cells was 26muM with a therapeutic index of 36 [2].

Chemical compound and disease context of Scutellarin


Biological context of Scutellarin


Anatomical context of Scutellarin


Associations of Scutellarin with other chemical compounds


Gene context of Scutellarin

  • Levels of malondialdehyde and protein kinase C activities were markedly higher and antioxidant enzyme activities such as superoxide dismutase, catalase as well as glutathione peroxidase were significantly lower in the kidneys of diabetic rats than of the control group, breviscapine administration markedly remitted these changes [8].
  • CONCLUSION: Scutellarin has protective effects for cerebral injury through regulating the expression of NOS isoforms and angiogenic molecules [7].
  • Results also showed that hydrogen peroxide increased activity of cNOS, which was markedly inhibited by scutellarin [18].
  • Western blot analysis noted that the expression of transforming growth factor beta1 protein was increased 1.8-fold in the kidney in diabetic rats, breviscapine treatment could reduce increased expression of TGF-beta1 protein by 47% [8].
  • The aims of the present study were to investigate the regulatory function of scutellarin on production of nitric oxide (NO) as well as activities of constitutive NO synthase (cNOS) and inducible NO synthase (iNOS) in early stages of neuron damage induced by hydrogen peroxide [18].

Analytical, diagnostic and therapeutic context of Scutellarin


  1. Scutellarin attenuates oxidative glutamate toxicity in PC12 cells. Hong, H., Liu, G.Q. Planta Med. (2004) [Pubmed]
  2. The anti-HIV-1 effect of scutellarin. Zhang, G.H., Wang, Q., Chen, J.J., Zhang, X.M., Tam, S.C., Zheng, Y.T. Biochem. Biophys. Res. Commun. (2005) [Pubmed]
  3. A study of the cardioprotective effect of breviscapine during hypoxia of cardiomyocytes. Li, X.L., Li, Y.Q., Yan, W.M., Li, H.Y., Xu, H., Zheng, X.X., Guo, D.W., Tang, L.K. Planta Med. (2004) [Pubmed]
  4. In vitro studies of baicalin alone or in combination with Salvia miltiorrhiza extract as a potential anti-cancer agent. Franek, K.J., Zhou, Z., Zhang, W.D., Chen, W.Y. Int. J. Oncol. (2005) [Pubmed]
  5. Protective effects of breviscapine on ischemic vascular dementia in rats. Xiong, Z., Liu, C., Wang, F., Li, C., Wang, W., Wang, J., Chen, J. Biol. Pharm. Bull. (2006) [Pubmed]
  6. Pharmacokinetics and metabolism of the flavonoid scutellarin in humans after a single oral administration. Chen, X., Cui, L., Duan, X., Ma, B., Zhong, D. Drug Metab. Dispos. (2006) [Pubmed]
  7. Neuroprotective effects of scutellarin on rat neuronal damage induced by cerebral ischemia/reperfusion. Hu, X.M., Zhou, M.M., Hu, X.M., Zeng, F.D. Acta Pharmacol. Sin. (2005) [Pubmed]
  8. Renoprotective Effect of Breviscapine through Suppression of Renal Macrophage Recruitment in Streptozotocin-Induced Diabetic Rats. Qi, X.M., Wu, G.Z., Wu, Y.G., Lin, H., Shen, J.J., Lin, S.Y. Nephron Exp. Nephrol. (2006) [Pubmed]
  9. Prodrugs of scutellarin: Ethyl, benzyl and N,N-diethylglycolamide ester synthesis, physicochemical properties, intestinal metabolism and oral bioavailability in the rats. Cao, F., Guo, J.X., Ping, Q.N., Liao, Z.G. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences (2006) [Pubmed]
  10. Protection against hydrogen peroxide-induced cytotoxicity in PC12 cells by scutellarin. Hong, H., Liu, G.Q. Life Sci. (2004) [Pubmed]
  11. Distribution of liposomal breviscapine in brain following intravenous injection in rats. Lv, W., Guo, J., Li, J., Huang, L., Ping, Q. International journal of pharmaceutics. (2005) [Pubmed]
  12. Protective effects of scutellarin on superoxide-induced oxidative stress in rat cortical synaptosomes. Liu, H., Yang, X.L., Wang, Y., Tang, X.Q., Jiang, D.Y., Xu, H.B. Acta Pharmacol. Sin. (2003) [Pubmed]
  13. Amelioration of graft ischmia-reperfusion injury by breviscapine in rat small bowel transplantation. Ma, R., Sun, J.L., Zhang, X.Q., Dai, Y., Sun, J.Z. Transplant. Proc. (2006) [Pubmed]
  14. Differential effects of new breviscapine on arachidonic acid metabolisms in blood cells and endothelial cells. Wang, Z.Y., Chen, D.C., He, Y., Ruan, C.G., Zhang, R.W. Zhongguo yao li xue bao = Acta pharmacologica Sinica. (1993) [Pubmed]
  15. Determination of aglycone conjugated metabolites of scutellarin in rat plasma by HPLC. Huang, J., Li, N., Yu, Y., Weng, W., Huang, X. Journal of pharmaceutical and biomedical analysis. (2006) [Pubmed]
  16. Validation of an HPLC method for the determination of scutellarin in rat plasma and its pharmacokinetics. Hao, X., Cheng, G., Sun, J., Zou, M., Yu, J., Zhang, S., Cui, F. Journal of pharmaceutical and biomedical analysis. (2005) [Pubmed]
  17. Synthesis, characterization and in situ intestinal absorption of different molecular weight scutellarin-PEG conjugates. Zhou, Q., Jiang, X., Li, K., Fan, X. Die Pharmazie. (2006) [Pubmed]
  18. Effect of scutellarin on nitric oxide production in early stages of neuron damage induced by hydrogen peroxide. Liu, H., Yang, X., Tang, R., Liu, J., Xu, H. Pharmacol. Res. (2005) [Pubmed]
  19. Probing the binding of scutellarin to human serum albumin by circular dichroism, fluorescence spectroscopy, FTIR, and molecular modeling method. Tian, J., Liu, J., He, W., Hu, Z., Yao, X., Chen, X. Biomacromolecules (2004) [Pubmed]
  20. Multivesicular liposome formulation for the sustained delivery of breviscapine. Zhong, H., Deng, Y., Wang, X., Yang, B. International journal of pharmaceutics. (2005) [Pubmed]
  21. Determination of scutellarin in rat plasma by high-performance liquid chromatography with ultraviolet detection. Zhong, D., Yang, B., Chen, X., Li, K., Xu, J. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2003) [Pubmed]
WikiGenes - Universities